This post was originally published on this site
Pharmaceutical giant GlaxoSmithKline UK:GSK and Canadian vaccine maker Medicago have released promising results from their Phase 2 COVID-19 clinical trial.
In a joint statement posted on Tuesday, they say the study shows trial participants have 10 times more antibodies in their systems than patients recovering from COVID-19. They reported that there were no severe adverse reactions.
It…
